Upcoming conferences
Our CEO, Pierre Vandepapelière, will be attending BioVaria on April 28th in Munich. Pitch Monday 28th April 11:30 AM Our CEO, Pierre Vandepapelière, will be attending LSX World Congress on April 29-30 In London. Showcase Tuesday 29th April 12:00-12:15 Our CEO, Pierre Vandepapelière, will be attending the Swiss Biotech Day on May 5-6 in Basel. […]
Amyl Therapeutics is one of the 10 startups selected to pitch at BioVaria
We are proud to announce that Amyl Therapeutics is one of the 10 startups selected to pitch at the BioVaria conference in Munich on April 28, 2025. Our presentation will focus on our innovative technology, which we believe has the potential to transform the neurodegenerative research sector. Thank you to the BioVaria team for this […]
2025 AD/PD conference
Damien Toulorge, Julie Goemaere and Aditya Iyer attended the Alzheimer’s & Parkinson’s Diseases Conference in Vienna, Austria, from April 1-5, 2025. Aditya Iyer, our Senior Project Manager, presented a poster describing Amyl technology and results. The team came back even more convinced that Amyl strategy is the best to find a universal treatment for neurodegenerative […]
Laborama 2025 in Brussels
Last week, our laboratory team had the pleasure of attending Laborama 2025 at Brussels Expo. They explored cutting-edge innovations and connected with passionate professionals in the field. Beyond the insights and networking, this event was also a wonderful occasion for the lab team to spend quality time together, strengthening their collaboration and shared vision.
Fire training
Last week, our R&D Director, Julie Goemaere, and our Senior Project Manager, Aditya Iyer, attended a fire training. The fire triangle and all the other basics in the event of a fire no longer hold any secrets for them ! Amyl puts safety and well-being at work at the heart of its preoccupations. Reacting quickly […]
First year at the LégiaPark
On March 12th, Amyl Therapeutics celebrated its first year at the LégiaPark. Since the move, Amyl has grown to 9 team members, and welcomed Chiara, Damien, Sophia, Sandra and Dafni. Our team is growing, and our projects are evolving, primarily in the field of Alzheimer’s disease. We are dedicated to find an efficacious and safe […]
Bio-Neuroscience
Amyl Therapeutics had joined Bio-Neuroscience, a premier partnership and investment summit for the world’s leaders in drug discovery and development in the field of central nervous system (CNS) neuroscience. It took place from February 25 to 27, 2025 in Amsterdam. A great opportunity to connect with key people in neuroscience. We are eager to take […]
The Amyl Team – Who does what ?
Pierre Vandepapelière – CEO “As the CEO of Amyl Therapeutics, my role is to lead with vision, passion, and purpose. In a field as challenging as neurodegeneration, every decision brings us closer to potential breakthroughs that could one day impact the lives of patients, families, and communities. I’m proud to lead a team that’s committed […]
Bio-Europe Fall in Stockholm
We are excited to announce that Pierre Vandepapeliere, our CEO and Damien Toulorge, our Chief Scientific Officer, will be attending BioEurope 2024. This premier event brings together leaders in the biopharmaceutical industry to discuss innovation, partnership opportunities, and the future of biotech. We look forward to engaging with fellow professionals, sharing insights, and exploring collaborations […]
Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis
LIEGE, Belgium – June 3, 2021: Amyl Therapeutics (‘Amyl’), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq – a […]